All News

Patrick Borgen, MD, discussed using ctDNA for “molecular interception” to de-escalate surgery and minimize AEs in biology-driven breast cancer care.

Based on findings from LITESPARK-11, belzutifan/lenvatinib may represent a new option in previously treated renal cell carcinoma.

The phase 2 study aimed to compare the safety of pembrolizumab and radiation with or without olaparib in this high-risk population.

Despite differences in treatment tolerance across different RCC subgroups, survival outcomes were similar in a retrospective study.

Data from PEACE-2 may challenge the current definition of "very high-risk" localized prostate cancer without nodal disease involvement.

Sarah Poland, MD, discussed the divergence between the IMpassion130 and IMpassion131 trials and the critical role of confirmatory trials in oncology.

Data from RETAIN-1 and RETAIN-2 show the chemoradiotherapy or BCG may remain viable options in those with ctDNA negativity but evidence of local disease.

Phase 3 data support perioperative enfortumab vedotin plus pembrolizumab as a novel treatment option in MIBC regardless of eligibility for cisplatin.

The expansion of clinical trials evaluating proton-based radiotherapy could elucidate its benefits and increase its access across the US.

Retrospective data show that relapse-free survival outcomes were worse for patients with MDS/MPN compared with those who had other types of MDS.

Often, patients in middle-income settings, are the patients who are impacted most by insurance deductibles, according to Loretta Nastoupil, MD.

Relacorilant plus nab-paclitaxel improved PFS among patients with PROC who had progression after a PARP inhibitor or who were 65 years or older.

Explore the latest clinical data and therapeutic strategies for acral, mucosal, and uveal melanomas from Mark B. Faries, MD, FACS.

Results from the PEACE-3 trial found an extended OS after patients with metastatic castration-resistant prostate cancer were treated with enzalutamide/radium-223.

Experts review strategies for effective screening and other measures for limiting cancer incidence in observance of National Cancer Prevention Month.

Data from the CAPItello-281 trial may support capivasertib/abiraterone as a first-in-class targeted therapy in this metastatic hormone-sensitive prostate cancer population.

Yan Leyfman, MD, reviewed how toxicity management in hematologic oncology is shifting to phenotype- and mechanism-informed intervention.

Data from the phase 2 BRCAAway trial showed the longest survival with olaparib plus abiraterone/prednisone vs each agent given alone or sequentially.

Loretta Nastoupil, MD, reflected on some of the differences between practicing in a rural, community cancer center compared with a larger institutional center.

The FDA approved zongertinib in HER2-mutated NSCLC as part of its Commissioner's National Priority Voucher pilot program.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

The EGFR/HER3 bispecific ADC met the primary end points of PFS and OS in patients with advanced triple-negative breast cancer.

Experts review potential clinical advances highlighted at the 2026 ASCO Gastrointestinal Cancers Symposium.

Preliminary findings have shown an “unprecedented” result with blinatumomab in mixed phenotype acute leukemia, according to Ashkan Emadi, MD, PhD.

Sarah Poland, MD, discussed the transition of breast cancer from an "immunologically cold" tumor to a target for checkpoint inhibitors, highlighting the pivotal role of the KEYNOTE-012 trial.

Irtiza Sheikh, DO, sought to assess the impact of age and clinical setting on liso-cel efficacy in patients with large B-cell lymphoma.

The willingness-to-pay metric is a tool that varies by individual country, which is used to determine how much a patient might pay for their treatment.

A partial clinical hold has been placed on the phase 2 LINNET trial following the report of several serious safety events, including 1 treatment-related death.

James Larkin, MD, PhD, highlighted toxicities associated with immune checkpoint inhibitors in melanoma at a recent Physicians Education Resource meeting.

SRN-101, an AAV-based immuno-gene therapy, has received fast track designation for the treatment of recurrent high-grade glioma.